Statera Biopharma, Inc. (STAB)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2021 | 38.93 Million USD | 470.79% |
| 2020 | -2.58 Million USD | -273.13% |
| 2019 | -2.36 Million USD | 41.37% |
| 2018 | -4.79 Million USD | 14.3% |
| 2017 | -5.6 Million USD | 11.88% |
| 2016 | -6.35 Million USD | 41.1% |
| 2015 | -10.79 Million USD | 99.93% |
| 2014 | -14.42 Billion USD | 37.5% |
| 2013 | -23.07 Billion USD | 23.2% |
| 2012 | -30.04 Billion USD | -19.68% |
| 2011 | -25.1 Billion USD | -195636.56% |
| 2010 | -12.82 Million USD | 99.8% |
| 2009 | -6.38 Billion USD | 55.51% |
| 2008 | -14.34 Billion USD | -53037.88% |
| 2007 | -26.99 Million USD | -273.78% |
| 2006 | -7.22 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2022 Q2 | -2.6 Million USD | 58.42% |
| 2022 Q1 | -6.27 Million USD | -110.91% |
| 2022 Q3 | -1.27 Million USD | 51.12% |
| 2021 Q4 | 57.51 Million USD | 834.15% |
| 2021 Q2 | -6.02 Million USD | -16.08% |
| 2021 Q3 | -7.83 Million USD | -29.96% |
| 2021 FY | - USD | 470.79% |
| 2021 Q1 | -5.19 Million USD | -31.64% |
| 2020 Q4 | -3.94 Million USD | 31.07% |
| 2020 Q1 | -611.91 Thousand USD | 0.0% |
| 2020 Q2 | -299.02 Thousand USD | 51.13% |
| 2020 FY | - USD | -273.13% |
| 2020 Q3 | -5.72 Million USD | -1813.89% |
| 2019 Q3 | -518.39 Thousand USD | 32.82% |
| 2019 FY | - USD | 41.37% |
| 2019 Q1 | -790.17 Thousand USD | 0.0% |
| 2019 Q2 | -771.6 Thousand USD | 2.35% |
| 2018 Q3 | -1.26 Million USD | -18.7% |
| 2018 FY | - USD | 14.3% |
| 2018 Q1 | -1.83 Million USD | 0.0% |
| 2018 Q2 | -1.06 Million USD | 41.83% |
| 2017 FY | - USD | 11.88% |
| 2017 Q2 | -1.57 Million USD | 3.02% |
| 2017 Q1 | -1.61 Million USD | 0.0% |
| 2017 Q3 | -1.19 Million USD | 23.76% |
| 2016 Q3 | -714.13 Thousand USD | 52.21% |
| 2016 Q2 | -1.49 Million USD | 35.38% |
| 2016 Q1 | -2.31 Million USD | 0.0% |
| 2016 FY | - USD | 41.1% |
| 2015 FY | - USD | 99.93% |
| 2015 Q3 | -2.81 Million USD | 1.18% |
| 2015 Q2 | -2.85 Million USD | 13.91% |
| 2015 Q1 | -3.31 Million USD | 0.0% |
| 2014 Q3 | -3.43 Million USD | 14.3% |
| 2014 Q1 | -3.51 Million USD | 0.0% |
| 2014 FY | - USD | 37.5% |
| 2014 Q2 | -4.01 Million USD | -14.02% |
| 2013 Q3 | -5.85 Million USD | 13.58% |
| 2013 Q2 | -6.77 Million USD | 9.01% |
| 2013 FY | - USD | 23.2% |
| 2013 Q1 | -7.44 Million USD | 0.0% |
| 2012 Q3 | -7.84 Million USD | 14.41% |
| 2012 Q2 | -9.16 Million USD | -22.45% |
| 2012 Q1 | -7.48 Million USD | 0.0% |
| 2012 FY | - USD | -19.68% |
| 2011 Q3 | -6.96 Million USD | -5.04% |
| 2011 Q1 | -5.11 Million USD | 0.0% |
| 2011 FY | - USD | -195636.56% |
| 2011 Q2 | -6.62 Million USD | -29.64% |
| 2010 Q3 | -967.7 Thousand USD | 63.07% |
| 2010 FY | - USD | 99.8% |
| 2010 Q1 | -1.45 Million USD | 0.0% |
| 2010 Q2 | -2.62 Million USD | -79.87% |
| 2009 FY | - USD | 55.51% |
| 2009 Q2 | -2.42 Million USD | -84.35% |
| 2009 Q1 | -1.31 Million USD | 0.0% |
| 2009 Q3 | -1.09 Million USD | 54.99% |
| 2008 Q1 | -4.06 Million USD | 0.0% |
| 2008 FY | - USD | -53037.88% |
| 2008 Q3 | -2.87 Million USD | 28.16% |
| 2008 Q2 | -4 Million USD | 1.65% |
| 2007 Q3 | -17.01 Million USD | -109.71% |
| 2007 Q1 | -4.1 Million USD | 0.0% |
| 2007 FY | - USD | -273.78% |
| 2007 Q2 | -8.11 Million USD | -97.58% |
| 2006 FY | - USD | 0.0% |
| 2006 Q2 | -1.28 Million USD | 0.0% |
| 2006 Q3 | -1.66 Million USD | -29.29% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| America Great Health | -447.29 Thousand USD | 8804.594% |
| Ampio Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | 231.956% |
| Biora Therapeutics, Inc. | -114.05 Million USD | 134.137% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | 347.034% |
| Better Therapeutics, Inc. | -38.26 Million USD | 201.759% |
| Calithera Biosciences, Inc. | -38.26 Million USD | 201.751% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | 317.677% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | 215.421% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | 216.666% |
| Evelo Biosciences, Inc. | -106.34 Million USD | 136.612% |
| Evolutionary Genomics, Inc. | -913.47 Thousand USD | 4362.299% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | 219.866% |
| Galera Therapeutics, Inc. | -46.69 Million USD | 183.387% |
| Innovation1 Biotech Inc. | -5.68 Million USD | 785.023% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | 338.847% |
| Molecular Templates, Inc. | 1.43 Million USD | -2622.724% |
| Navidea Biopharmaceuticals, Inc. | -13.87 Million USD | 380.61% |
| NexImmune, Inc. | -28.16 Million USD | 238.226% |
| Orgenesis Inc. | -60.71 Million USD | 164.124% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 175.905% |
| Point of Care Nano-Technology, Inc. | -73.41 Thousand USD | 53133.335% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 341.154% |
| Scopus BioPharma Inc. | -11.71 Million USD | 432.404% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 107.211% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | 665.586% |
| Trevena, Inc. | -35.28 Million USD | 210.335% |
| Vaxxinity, Inc. | -56.05 Thousand USD | 69563.44% |
| Vaccinex, Inc. | -19.74 Million USD | 297.159% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | 3818.794% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | 183.084% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 636.072% |